AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Rhea-AI Summary

AIM ImmunoTech announced the release of a new CEO Corner segment on their website. CEO Thomas Equels provided updates on the Phase 1b/2 DURIPANC study for a combination therapy of Ampligen and AstraZeneca's Imfinzi targeting late-stage pancreatic cancer. Additionally, the company reported a stockholders' equity of $6.9 million as a result of recent financings. The full CEO Corner segment can be accessed on the company's website.

Positive

• AIM ImmunoTech reported a stockholders' equity of $6.9 million due to recent financings.

Negative

• None.

OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study of Ampligen and AstraZeneca’s Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders’ equity of $6.9 million.

The CEO Corner segment is now available here. 

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

FAQ

What updates did AIM ImmunoTech provide in the latest CEO Corner segment?

AIM ImmunoTech provided updates on the Phase 1b/2 DURIPANC study for late-stage pancreatic cancer and announced a stockholders' equity of $6.9 million due to recent financings.

When was the new CEO Corner segment released by AIM ImmunoTech?

The new CEO Corner segment was released on July 3, 2024.

What is the focus of the AIM ImmunoTech Phase 1b/2 DURIPANC study?

The Phase 1b/2 DURIPANC study focuses on the combination therapy of Ampligen and AstraZeneca’s Imfinzi for late-stage pancreatic cancer.

What is the current stockholders' equity of AIM ImmunoTech?

AIM ImmunoTech's current stockholders' equity is $6.9 million.